Literature DB >> 19661273

Th17 cells in ovarian cancer.

David H Munn1.   

Abstract

Entities:  

Year:  2009        PMID： 19661273     DOI： 10.1182/blood-2009-06-224246

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage?

Authors:  Martin J Cannon; Hannah Goyne; Pamela J B Stone; Maurizio Chiriva-Internati
Journal:  Expert Opin Biol Ther       Date:  2011-01-28       Impact factor: 4.388

Review 2.  T(H)17 cells in tumour immunity and immunotherapy.

Authors:  Weiping Zou; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2010-04       Impact factor: 53.106

3.  Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer.

Authors:  Hannah Goyne; Pamela J B Stone; Martin J Cannon
Journal:  Immunotherapy       Date:  2011-07       Impact factor: 4.196

4.  Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.

Authors:  Maurizio Chiriva-Internati; Yuefei Yu; Leonardo Mirandola; Marjorie R Jenkins; Caroline Chapman; Martin Cannon; Everardo Cobos; W Martin Kast
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

5.  Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen.

Authors:  Martin J Cannon; Hannah E Goyne; Pamela J B Stone; Laura J Macdonald; Lindsey E James; Everardo Cobos; Maurizio Chiriva-Internati
Journal:  Cancer Immunol Immunother       Date:  2013-01-25       Impact factor: 6.968

6.  Ovarian tumor ascites CD14+ cells suppress dendritic cell-activated CD4+ T-cell responses through IL-10 secretion and indoleamine 2,3-dioxygenase.

Authors:  Hannah E Goyne; Pamela J B Stone; Alexander F Burnett; Martin J Cannon
Journal:  J Immunother       Date:  2014-04       Impact factor: 4.456

Review 7.  Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.

Authors:  Kinga Majchrzak; Michelle H Nelson; Stefanie R Bailey; Jacob S Bowers; Xue-Zhong Yu; Mark P Rubinstein; Richard A Himes; Chrystal M Paulos
Journal:  Cancer Immunol Immunother       Date:  2016-01-29       Impact factor: 6.968

Review 8.  Th17 cells in cancer: the ultimate identity crisis.

Authors:  Stefanie R Bailey; Michelle H Nelson; Richard A Himes; Zihai Li; Shikhar Mehrotra; Chrystal M Paulos
Journal:  Front Immunol       Date:  2014-06-17       Impact factor: 7.561

9.  Antitumor immunity of low-dose cyclophosphamide: changes in T cells and cytokines TGF-beta and IL-10 in mice with colon-cancer liver metastasis.

Authors:  Xiao-Ming Huang; Nan-Rong Zhang; Xu-Tao Lin; Cai-Yan Zhu; Yi-Feng Zou; Xiao-Jian Wu; Xiao-Sheng He; Xiao-Wen He; Yun-Le Wan; Ping Lan
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-12-05

Review 10.  Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer.

Authors:  Hannah E Goyne; Martin J Cannon
Journal:  Front Immunol       Date:  2013-11-18       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.